‘Antiquated’ Regulations Slowing Adoption of Innovative Clinical Trial Approaches

The current regulations were written when clinical trials involved far fewer entities, and a certain amount of ‘contortion’ is necessary when sponsors are trying to introduce decentralized, community-based and other modern elements, the FDA’s Kevin Bugin says in an interview with the Pink Sheet.

Contortionist
A certain amount of contortion is involved in applying novel clinical trial approaches under current regs. • Source: Shutterstock

The US Food and Drug Administration’s recently launched Center for Clinical Trial Innovation (C3TI) is eyeing ways to make adoption of community-based, decentralized and other innovative trial approaches less of a contortion exercise due to outdated regulations.

Current standards do not preclude adoption of innovative trial designs and approaches, but they also do not make it easy,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

More from Conferences